337 related articles for article (PubMed ID: 27932505)
1. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
[TBL] [Abstract][Full Text] [Related]
2. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
[TBL] [Abstract][Full Text] [Related]
3. Differentiating between Glioblastoma and Primary CNS Lymphoma Using Combined Whole-tumor Histogram Analysis of the Normalized Cerebral Blood Volume and the Apparent Diffusion Coefficient.
Bao S; Watanabe Y; Takahashi H; Tanaka H; Arisawa A; Matsuo C; Wu R; Fujimoto Y; Tomiyama N
Magn Reson Med Sci; 2019 Jan; 18(1):53-61. PubMed ID: 29848919
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation.
Kickingereder P; Sahm F; Wiestler B; Roethke M; Heiland S; Schlemmer HP; Wick W; von Deimling A; Bendszus M; Radbruch A
AJNR Am J Neuroradiol; 2014 Aug; 35(8):1503-8. PubMed ID: 24722313
[TBL] [Abstract][Full Text] [Related]
5. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
[TBL] [Abstract][Full Text] [Related]
7. T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status.
Arevalo-Perez J; Thomas AA; Kaley T; Lyo J; Peck KK; Holodny AI; Mellinghoff IK; Shi W; Zhang Z; Young RJ
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2256-61. PubMed ID: 26338913
[TBL] [Abstract][Full Text] [Related]
8. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma and atypical glioblastoma: Differentiation using radiomics approach.
Suh HB; Choi YS; Bae S; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Eur Radiol; 2018 Sep; 28(9):3832-3839. PubMed ID: 29626238
[TBL] [Abstract][Full Text] [Related]
10. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
[TBL] [Abstract][Full Text] [Related]
11. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
[TBL] [Abstract][Full Text] [Related]
12.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
13. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
[TBL] [Abstract][Full Text] [Related]
14. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of enhancement-perfusion mismatch in differentiation of CNS lymphomas from other enhancing malignant tumors of the brain.
Goyal P; Kumar Y; Gupta N; Malhotra A; Gupta S; Gupta S; Mangla M; Mangla R
Quant Imaging Med Surg; 2017 Oct; 7(5):511-519. PubMed ID: 29184763
[TBL] [Abstract][Full Text] [Related]
16. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
[TBL] [Abstract][Full Text] [Related]
17. Machine Learning-based Texture Analysis of Contrast-enhanced MR Imaging to Differentiate between Glioblastoma and Primary Central Nervous System Lymphoma.
Kunimatsu A; Kunimatsu N; Yasaka K; Akai H; Kamiya K; Watadani T; Mori H; Abe O
Magn Reson Med Sci; 2019 Jan; 18(1):44-52. PubMed ID: 29769456
[TBL] [Abstract][Full Text] [Related]
18. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
19. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
[TBL] [Abstract][Full Text] [Related]
20. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
